NOVEL BIFIDOBACTERIUM BREVE JKL2022 STRAIN AND METHOD FOR PRODUCING CONJUGATED LINOLEIC ACID USING THEREOF

Abstract

The present invention relates to a Bifidobacterium breve JKL2022 strain capable of mass-producing natural conjugated linoleic acid (CLA), and a method for mass-producing conjugated linoleic acid using the same. The method of the present invention makes it possible to easily produce natural CLA in large quantities and high purity of functional CLA in a linoleic acid solution (50 mg/ml) using bacterial cells or cell-free extracts. The cell or cell-free extract of Bifidobacterium breve JKL2022 strain of the present invention, and the conjugated linoleic acid (CLA) produced thereby can be widely used in probiotic compositions, pharmaceutical compositions, health functional food compositions, feed additive compositions, and food additive compositions.

Claims

1. A Bifidobacterium breve JKL2022 strain (KACC81214BP).

2. The Bifidobacterium breve JKL2022 strain (KACC81214BP) according to claim 1, wherein the strain is characterized by having the 16S rRNA represented by SEQ ID NO: 1.

3. The Bifidobacterium breve JKL2022 strain (KACC81214BP) according to claim 1, wherein the strain is characterized by converting linoleic acid (LA) to conjugated linoleic acid (CLA).

4. The Bifidobacterium breve JKL2022 strain (KACC81214BP) according to claim 3, wherein the conjugated linoleic acid (CLA) is characterized by including a conjugated double bond at the cis-9/trans-11 position.

5. A method for converting linoleic acid (LA) to conjugated linoleic acid (CLA) comprising the following steps: 1) a step of obtaining cells by culturing Bifidobacterium breve JKL2022 strain; and 2) a step of adding linoleic acid to the medium for culturing Bifidobacterium breve JKL2022 strain, adding the cells obtained in step 1) thereto, and then culturing thereof.

6. A method for converting linoleic acid (LA) to conjugated linoleic acid (CLA) comprising the following steps: 1) a step of obtaining cells by culturing Bifidobacterium breve JKL2022 strain; 2) a step of obtaining a cell-free extract of Bifidobacterium breve JKL2022 strain by crushing the cells obtained in step 1); and 3) a step of adding linoleic acid to the medium for culturing Bifidobacterium breve JKL2022 strain, adding the cell free extract obtained in step 2) thereto, and then culturing thereof.

7. The method for converting LA to CLA according to claim 5, wherein the CLA is characterized by including a conjugated double bond at the cis-9/trans-11 position.

8. The method for converting LA to CLA according to claim 5, wherein the pH is 7 to 10.

9. The method for converting LA to CLA according to claim 6, wherein the pH is 5 to 7.5.

10. A pharmaceutical composition comprising the Bifidobacterium breve JKL2022 strain (KACC81214BP) of claim 1, or a cell or cell-free extract thereof as an active ingredient for improving immune function or for preventing or treating cancer, arteriosclerosis, diabetes, obesity, or Alzheimer disease.

11. A health functional food comprising the Bifidobacterium breve JKL2022 strain (KACC81214BP) of claim 1, or a cell or cell-free extract thereof as an active ingredient for improving immune function or for preventing or treating cancer, arteriosclerosis, diabetes, obesity, or Alzheimer disease.

12. A probiotic composition comprising the Bifidobacterium breve JKL2022 strain (KACC81214BP) of claim 1, or a cell or cell-free extract thereof as an active ingredient.

13. A pharmaceutical composition comprising the Bifidobacterium breve JKL2022 strain (KACC81214BP) of claim 1, or a cell or cell-free extract thereof as an active ingredient for improving immune function or for preventing or treating cancer, arteriosclerosis, diabetes, obesity, or Alzheimer disease.

14. An animal feed additive composition comprising the Bifidobacterium breve JKL2022 strain (KACC81214BP) of claim 1, or a cell or cell-free extract thereof as an active ingredient.

15. An animal food additive composition comprising the Bifidobacterium breve JKL2022 strain (KACC81214BP) of claim 1, or a cell or cell-free extract thereof as an active ingredient.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0023] FIG. 1 is a graph showing the results of comparing the amount of CLA produced through the culture process for each strain.

[0024] FIG. 2a is a graph showing the results of confirming the CLA isomers of the CLA standard mixture using GC/FID and Silver ion impregnated HPLC.

[0025] FIG. 2b is a graph showing the results of confirming the CLA isomers of the sample produced by Bifidobacterium breve JKL2022 strain according to the present invention using GC/FID and Silver ion impregnated HPLC.

[0026] FIG. 2c is a graph showing the results of confirming the CLA isomers produced using a method of co-injection after mixing the CLA produced by Bifidobacterium breve JKL2022 strain with a standard product.

[0027] FIG. 2d is a set of graphs showing the results of confirming that LA was converted to isomeric CLA by culturing Bifidobacterium breve JKL2022 strain for 24 hours according to the present invention.

[0028] FIG. 3 is a graph showing the structure of the CLA isomers produced by Bifidobacterium breve JKL2022 strain using GC-MS according to the present invention.

[0029] FIG. 4 is a graph showing the results of comparing the CLA production capacity of Bifidobacterium breve JKL2022 strain cells with other strains according to the present invention.

[0030] FIG. 5 is a set of graphs showing the results of confirming the CLA production and conversion rate by Bifidobacterium breve JKL2022 strain cells according to the present invention by the concentration of added LA. (A) LA conc.: 1.0 mg/mL; (B) LA conc.: 2.5 mg/mL; (C) LA conc.: 5.0 mg/mL; (D) LA conc.: 10 mg/mL.

[0031] FIG. 6 is a graph showing the results of increasing the concentration of cells and the concentration of LA, a substrate, to optimize the CLA production conditions by Bifidobacterium breve JKL2022 strain cells according to the present invention.

[0032] FIG. 7 is a graph showing the results of confirming the optimal pH for the CLA production by Bifidobacterium breve JKL2022 strain cells according to the present invention.

[0033] FIG. 8 is a graph showing the results of comparing the CLA production capacity of the cell-free extract prepared by cell disintegration of Bifidobacterium breve JKL2022 strain with the other comparative strains according to the present invention.

[0034] FIG. 9 is a graph showing the results of confirming the optimal pH for the CLA production by the cell-free extract prepared by cell disintegration of Bifidobacterium breve JKL2022 strain according to the present invention.

[0035] FIG. 10 is a graph showing the results of confirming the optimal temperature for the CLA production by the cell-free extract prepared with cell disintegration of Bifidobacterium breve JKL2022 strain according to the present invention.

BEST MODE FOR CARRYING OUT THE INVENTION

1. To Achieve the Objective of the Present Invention, the Present Invention Provides a Novel Bifidobacterium breve JKL2022 Strain (KACC 81214BP).
1-1. Isolation of a Novel Bifidobacterium breve JKL2022 Strain

[0036] The above strain was isolated from the feces of a healthy Korean infant under breastfeeding. The appropriately diluted fecal samples were plated and cultured to isolate a pure strain.

[0037] For the pure strains isolated, the presence of a gene encoding F6PPK (fructose-6-phosphate phosphoketolase) common among Bifidobacterium strains was confirmed by PCR (genus-specific PCR), and the strains belonging to the Bifidobacterium genus were first identified. Bifidobacterium breve strains were finally isolated and identified by species-specific PCR using a primer set prepared based on 16S rRNA gene sequence information.

[0038] The new strain of the present invention has the 16S rRNA gene nucleotide sequence represented by SEQ. ID. NO: 1.

[0039] The CLA production capacity of the newly isolated and identified Bifidobacterium breve strains was compared with previously reported strains, and the strains with excellent CLA production capacity were selected. Among them, the strain of the present invention had the best CLA production capacity (see FIG. 1).

[0040] The genus and species were identified through BLAST search by analyzing the 16S rRNA gene nucleotide sequence. The JKL2022 strain was deposited at Korean Agricultural Culture Collection (KACC), National Institute of Agricultural Sciences (NAS) as Bifidobacterium breve JKL2022 (KACC 81214BP) on May 11, 2022.

1-2. CLA Produced by Bifidobacterium breve JKL2022 Strain

[0041] For the selected strains, the fatty acid produced by each strain was analyzed by GC-FID (Agilent 7890A) to confirm again whether the strain could produce CLA from LA, and an additional confirmation experiment for the CLA isomer produced was conducted using silver ion impregnated HPLC (HPLC, Shimadzu, Tokyo, Japan). In addition, to reconfirm the double bond position of CLA, fatty acids were extracted, and GC-MS analysis was performed with methyl esterified samples.

[0042] The content of each fatty acid on the GC chromatogram obtained by performing GC analysis was quantified by comparing the peak areas of heptadecanoic acid (C17:0), an internal standard, with the peak area of each fatty acid (see FIGS. 2 and 3).

[0043] From the above experiments, it was confirmed that most of the fatty acid obtained according to the present invention is c9, t11-conjugated linoleic acid.

2. The Present Invention Provides a Method for Producing CLA Using a Novel Bifidobacterium breve JKL2022 Strain.

[0044] The present invention also provides a method for producing conjugated linoleic acid comprising a step of culturing the strain of the present invention. The strain is preferably a Bifidobacterium breve JKL2022 strain (accession number: KACC 81214BP). As a method for culturing the strain of the present invention, a method commonly used in industry can be used.

2-1. A Method Using Cells

[0045] 1 ml of Bifidobacterium breve JKL2022 strain culture product obtained through enrichment culture was centrifuged and washed to obtain a microbial whole cell pellet, and this pellet was suspended in a reaction buffer containing LA at a concentration of 1.0 mg/ml. Then, the conversion rate (%) of LA to CLA under the CLA production conditions (pH: 7.0, reaction temperature: 30 C., reaction time: 30 minutes) using the cells was confirmed (see FIG. 4)

[0046] As shown in FIG. 1, when LA was added to the medium in which the strain was cultured continuously, CLA was also produced in small amounts in other strains. However, when the cells obtained by culturing the strain were added and cultured, it was found that CLA was not produced in other strains that showed the ability to produce CLA by culturing the strain (see FIG. 10).

[0047] When microbial cells were used as a whole-cell biocatalyst, the production of CLA was confirmed as a characteristic of only Bifidobacterium breve JKL2022 strain according to the present invention (see FIG. 4).

[0048] As shown in FIG. 5, CLA production and conversion rate of the strain according to the concentration of LA while fixing the concentration of the microbial cells and increasing the amount of LA were investigated. It was confirmed that CLA was produced at a conversion rate of almost 100% within 30 minutes even if the concentration of LA in the reaction solution was increased to 5 mg/ml. A conversion rate of 70% (7 mg/ml CLA) was also confirmed at the LA concentration of 10 mg/ml.

[0049] As shown in FIG. 6, it was confirmed that almost all LA could be converted to CLA in one hour of reaction even if the concentration of the cells was increased by 5 times and the concentration of LA was 25 mg/ml.

[0050] Considering that an upper limit of LA concentration that can be added to the medium is up to 0.5 mg/ml in the production of CLA through the fermentation process of conventional strains, it can be seen as a very remarkable effect.

[0051] The production rate of CLA using Bifidobacterium breve JKL2022 cells was about 79 times higher than that obtained through the culture process of Bifidobacterium breve JKL2022 strain. The fact that the reaction using whole cells takes only 1 hour, while the production of CLA through culture process takes 24 hours, is also a big advantage.

[0052] As shown in FIG. 7, the pH conditions for CLA production using the whole cells were pH 7-10, preferably pH 9.0.

2-2. A Method Using Cell-Free Extract

[0053] After centrifuging the culture product obtained by inoculating the strain activated through subculture in a medium (200 ml), the supernatant, the medium component, was discarded, and the cells at the bottom were recovered and washed.

[0054] The washed cells were resuspended in a PBS solution, and the cells were disintegrated by ultrasonication. After centrifugation of the disintegrated cells, the supernatant was recovered to prepare a cell-free extract (CFE) and used as a crude enzyme solution for CLA production.

[0055] As shown in FIG. 8, it was found that the CLA production capacity of the cell-free extract of Bifidobacterium breve JKL2022 strain according to the present invention was better than those of the comparative strains.

[0056] As shown in FIG. 9, the pH conditions for CLA production using the cell-free extract of the strain were pH 5-7.5, preferably pH 5.5-7, and most preferably pH 6.5.

[0057] As shown in FIG. 10, the temperature conditions for CLA production using the cell-free extract of the strain were 20-50 C., preferably 30-45 C., and most preferably 40 C.

3. The Present Invention Provides Probiotic Preparations (Pharmaceutical Composition, Health Functional Food Composition, Food) Comprising a Novel Bifidobacterium breve JKL2022 Strain.

[0058] The strain (Bifidobacterium breve JKL2022) of the present invention produces CLA, and the produced CLA is known to reduce the incidence of arteriosclerosis (Artery. 1997. 22:266-277), improve immune function (J. Nut. 1999. 129:32-38), has anticancer activity (Anticancer research. 1997. 17:969-973), exhibit excellent therapeutic effects on diseases such as diabetes, and suppress obesity by reducing body fat (AM. J. Registered Patent 10-1655855-6-Physiol. 1998. 275: R667-R672). More recently anti-Alzheimer's disease effect by c9, t11 CLA is also reported (Sci. Report. 2011. 11:9749). Therefore, the strain (Bifidobacterium breve JKL2022) of the present invention, its cell or cell-free extract can be used as a pharmaceutical composition for improving immune function or for preventing or treating cancer, arteriosclerosis, diabetes, obesity, and Alzheimer disease.

[0059] The probiotic preparation of the present invention strain can be applied to all uses known as the functionality of the conventional CLA. Specifically, the probiotic preparation can be applied to pharmaceutical compositions, health functional food compositions, and foods. The food can be specifically applied to cheese, yogurt, milk powder, ice cream, and the like, and most preferably to cheese and yogurt.

[0060] The dosage or intake of the pharmaceutical composition of the present invention is preferably 60 to 130 M (Cancer Epidemiol. Biol. Prev. 2000. 9:689-696), and the dosage or intake of the functional food is preferably 3.4 to 6 g/day (J. Nutr. 2000. 130:2943-2948) but can be increased or decreased as necessary. The pharmaceutical composition of the present invention is safely absorbed into the body regardless of the amount of intake. The dosage or intake can be adjusted according to various factors, including the type and content of active ingredients and other components in the pharmaceutical composition, the type of formulation, the patient's age, weight, general health status, gender and diet, administration time, route and composition secretion rate, treatment period, and drugs used concurrently. When the pharmaceutical composition of the present invention is administered to a human body, there is no concern about side effects compared to the foods and medicines containing chemically synthesized CLA.

[0061] The food or pharmaceutical composition of the present invention can include one or more pharmaceutically or sitologically acceptable carriers in addition to an active ingredient selected among the stomach cancer inhibitors, such as saline, sterilized water, Ringer's solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture comprising one or more of those components. If necessary, other common additives such as antioxidants, buffers, and bacteriostatic agents can be added. The composition of the present invention can be formulated in different forms including aqueous solutions, suspensions and emulsions for injection, pills, capsules, granules, or tablets by mixing with diluents, dispersing agents, surfactants, binders, and lubricants. The composition can further be preferably formulated in suitable forms according to each disease or component by using an appropriate method in the art or by using a method disclosed in Remington's Pharmaceutical Science (the newest edition), Mack Publishing Company, Easton PA.

[0062] The formulation form of the pharmaceutical composition of the present invention can be granules, powders, coated tablets, tablets, capsules, decoctions, extracts, suppositories, syrups, juices, suspensions, emulsions, sustained-release formulations of active ingredient, etc.

[0063] In addition, the strain of the present invention can be added to food or medicine in the form of live cells as well as dead cells (parabiotics). This is because the strain of the present invention has the characteristics of accumulating a significant amount of CLA in cells while secreting CLA into the culture medium or reaction solution. Accordingly, since CLA can be indirectly produced by adding the cultured strain in the LA-added medium to various compositions such as food and medicine as an active ingredient, it can promote the development of functional products containing large amounts of CLA.

[0064] The present invented strain, Bifidobacterium breve JKL2022, its cell or cell-free extract can be used as an animal feed composition.

[0065] The present invented strain, Bifidobacterium breve JKL2022, its cell or cell-free extract can be used as a food additive composition.

MODE FOR THE INVENTION

[0066] Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are only for illustrating the present invention, and the contents of the present invention are not limited thereto.

Example 1: Isolation and Identification of Strains of the Present Invention

[0067] To isolate the strain of the present invention, the feces of a healthy Korean infant under breastfeeding were collected. To isolate Bifidobacterium breve strain known to have high CLA production capacity by previous studies, appropriately diluted fecal samples were plated on a TOS (Trans-galactosylated oligosaccharide) propionate agar medium (Yakult Pharmaceutical, Japan), a Bifidobacterium selection medium, after decimal dilution using an anaerobic microbial diluent, cultured anaerobically at 37 C. for 48 hours, and then typical colonies were taken for pure isolation.

[0068] For the pure isolated strains, the presence of a gene encoding F6PPK (fructose-6-phosphate phosphoketolase) common among Bifidobacterium strains was confirmed by PCR (genus-specific PCR), and the strains belonging to the Bifidobacterium genus were first identified. Bifidobacterium breve strains were finally isolated and identified by species-specific PCR using a primer set prepared based on 16S rRNA gene sequence information.

[0069] The CLA production capacity of the newly isolated and identified Bifidobacterium breve strains was compared with previously reported strains, and a strain with excellent CLA production capacity was selected and named as JKL2022. The genus and species were identified through BLAST search by analyzing the nucleotide sequence of the 16S rRNA gene for the strain of the present invention. As a result, JKL2022 was determined to be Bifidobacterium breve. As shown in Table 1, the newly isolated strain had a difference of 1 to 5 bases in the 16S rRNA gene nucleotide sequence from the strains previously reported to have high CLA production capacity, so the novelty of the strain was recognized. The JKL2022 strain was deposited at Korean Agricultural Culture Collection (KACC), National Institute of Agricultural Sciences (NAS) as Bifidobacterium breve JKL2022 (KACC 81214BP) on May 11, 2022.

TABLE-US-00001 TABLE 1 Novel strain identification by comparing 16S rRNA gene sequence Different 16S rRNA gene base Strains compared match rate number Bifidobacterium breve KCTC3220.sup.T 99.93% (1452/1453) 1 Bifidobacterium breve DSM20091 99.66% (1448/1453) 5 Bifidobacterium breve NCFB2257 99.86% (1451/1453) 2 Bifidobacterium breve NCFB2258 99.66% (1448/1453) 5 Bifidobacterium breve ATCC15698 99.66% (1448/1453) 5 Bifidobacterium breve LMC520 99.86% (1451/1453) 2 Bifidobacterium breve NCTC11815 99.86% (1451/1453) 2 Bifidobacterium breve JCM7017 99.72% (1450/1453) 4 Bifidobacterium breve JCM7019 99.66% (1448/1453) 5 Bifidobacterium breve JCM1273 99.66% (1448/1453) 5

Example 2: Comparison ofBifidobacterium Breve JKL2022 with Other Strains

<2-1> Comparison of CLA Production Capacity of Bifidobacterium breve JKL2022 and Other Strains Through Microbial Culture

[0070] For the production of CLA, the above strain was inoculated into MRS medium (mMRS; Sigma) containing 0.05% L-cysteine HCl and activated through two rounds of subculture at 37 C. for 18 hours under anaerobic conditions where O.sub.2 was replaced with CO.sub.2. Then, the strain was inoculated into the new mMRS medium added with linoleic acid (LA), a substrate, at a concentration of 0.5 mg/mL, and cultured at 37 C. for 24 hours under anaerobic conditions to convert LA into CLA.

[0071] FIG. 1 is a graph showing the results of comparing the CLA conversion rate of Bifidobacterium breve JKL2022 strain according to the present invention with other Bifidobacterium breve strains. It has been reported that the amount of CLA produced by the prior art through the culture process of microorganisms increases with the growth of the strain. The amount of CLA produced by culture of Bifidobacterium breve JKL2022 strain according to the present invention was confirmed to be 0.33 mg/ml (conversion rate: 65.8%). Comparing the CLA production ability through Bifidobacterium cultures, the production was highest when using Bifidobacterium breve JKL2022 strain of the present invention (FIG. 1).

Example 3: Confirmation of c9, t11-CLA Isomers Through Structural Analysis of Produced CLA

<3-1> Pretreatment for Fatty Acid Analysis of Reactants (Methylation)

[0072] 1N NaOH or 1N HCl was added dropwise to 4 mL of the reactant to adjust the pH to 7.0, and 0.1 mL of an internal standard (C17:0; 10 mg/mL hexane) and 4 mL of an extraction solvent (hexane) were added thereto, mixed with 2 mL of saturated NaCl aqueous solution, shaken sufficiently, and allowed to stand for 30 minutes. Then, the sample was centrifuged (1,900g, 5 minutes) and the separated hexane layer was transferred to a new glass tube. The extract obtained after additionally extracting using 4 mL of extraction solvent (hexane) was transferred to the same glass tube, and nitrogen concentration was performed at 45 C. When the solvent was completely removed, 1 mL of 1.0% HCl in methanol was added and reacted at 60 C. for 30 minutes to perform fatty acid methylation. Upon completion of the reaction, a supernatant was obtained by extracting fatty acid methyl esters by adding 2 mL of saturated NaCl solution and 1 mL of hexane. To the supernatant obtained, a small amount of anhydrous sodium sulfate was added to remove moisture and transferred to a vial for GC analysis.

<3-2> Fatty Acid Identification and Quantification Experiments

1) GC/FID (Gas Chromatography/Flame Ionization Detector)

[0073] The fatty acid methyl ester obtained by the above method was analyzed by GC-FID (Agilent 7890A). At this time, Supelcowax-10 fused silica capillary column (100 m0.32 mm i.d., 0.25 m film thickness) was used as a column. Helium used as a moving phase was supplied at a rate of 1.2 mL/min. The temperature of the sample injector and detector was 260 C., and the temperature of the oven was raised from 190 C. to 240 C. at a rate of 4 C. per minute and then maintained. The fatty acid of each peak was first confirmed through the retention time of each fatty acid standard.

2) Silver Ion Impregnated HPLC

[0074] Further confirmation of the generated CLA isomers was performed using silver ion impregnated HPLC (HPLC, Shimadzu, Tokyo, Japan). The generated CLA was methyl esterified by the above method, and then three silver ion impregnated columns (ChromSpher 5 Lipids analytical silver-impregnated column, 4.6 mm i.d.250 mm stainless steel, 5 m particle size; Chrompack, Bridgewater, NJ, USA) were connected in series and used. As a moving phase, 0.1% acetonitrile in hexane was flowed at a rate of 1.0 mL/minute to perform analysis. To confirm the CLA isomer, the retention time was compared by analyzing the standard CLA isomer mixtures under the same conditions. In addition, the CLA isomer was further confirmed by performing silver ion impregnation HPLC using a method of simultaneously injecting a mixture of the standard and the CLA produced by the method of the present invention.

3) GC-MS (Gas Chromatography/Mass Spectrometry)

[0075] To reconfirm the location of the double bond of CLA, GC-MS was performed after 4,4-dimethyloxazoline (DMOX) derivatives of fatty acid methyl ester (FAMEs) were prepared. After methyl esterification of CLA produced by JKL2022 cells, DMOX derivatization reaction was performed again. About 10 mg of methyl esterified (FAMES) CLA was added to a test tube, and then 50 mg of 2-amino-2-methyl-1-propanol, a derivatization reagent, was added thereto. Thereafter, after purging with argon gas, the lid was tightly closed, and the reaction was carried out at 170 C. for 6 hours. After cooling to room temperature, diethyl ether/hexane (1:1, vol/vol; 5 mL) and distilled water (5 mL) were added to the test tube, shaken, and allowed to stand, and the obtained supernatant (diethyl ether/hexane) was recovered. A small amount of anhydrous sodium sulfate was added to the recovered supernatant to remove water, and the solvent was removed using nitrogen. 0.5 mL of the DMOX derivatives of fatty acids obtained was re-dissolved in 2,2,4-trimethylpentane, and GC-MS analysis was performed.

[0076] The DMOX derivatives of fatty acid methyl ester prepared by the above method were analyzed using gas chromatography-mass spectrometry (a Perkin-Elmer Auto System XL). At this time, a Supelcowax-10 fused silica capillary column (100 m0.32 mm i.d., 0.25 m film thickness) was used as a column. Helium used as a moving phase was supplied at a rate of 1.2 mL/min. The temperature of the sample injector and detector was 260 C., and the temperature of the oven was raised from 190 C. to 240 C. at a rate of 4 C. per minute and then maintained. The inlet, transfer line, and ion source temperatures were 260, 220, and 260 C., respectively, and the sample was ionized at 70 eV using the EI ionization mode.

4) Analysis of Fatty Acid Content Using GC-FID

[0077] GC analysis was performed on the sample obtained by extracting fatty acids and methyl esterified fatty acids under the above conditions of GC-FID. The content of each fatty acid obtained from GC chromatogram was quantified by comparing the peak area of the internal standard heptadecanoic acid (C17:0) and the peak area of each fatty acid.

[0078] As shown in FIG. 2D, it was confirmed that linoleic acid was converted into a completely new fatty acid in MRS broth using Bifidobacterium breve strain JKL2022. To confirm the type of fatty acid produced, the CLA standard mixture was analyzed by GC under the same conditions and compared with the standard retention time. It was primarily confirmed that the produced fatty acids were c9/t11 CLA isomers, along with trace amounts of c9/c11, and t9/t11. In addition, the structure of these fatty acids was compared and reconfirmed by comparative analysis with a standard CLA mixture whose structure is known using silver ion impregnated HPLC. In particular, an additional experiment was conducted by co-injecting a mixture of the CLA produced by Bifidobacterium breve JKL2022 strain and the standard products. As a result, it was further confirmed that the major isomers were c9/tI1-CLA with trace amounts of c9/c11 and t9/t11-CLA isomers.

[0079] FIG. 3 shows a mass chromatogram obtained by preparing a DMOX derivatives of fatty acids and analyzing thereof by GC-MS to confirm the number and position of double bonds located in the fatty acid of the CLA produced by Bifidobacterium breve JKL2022 strain. From this chromatogram, the molecular ion value was confirmed as m/z 333, indicating that it had a fatty acid structure with 18 carbon atoms and two double bonds. In addition, it was confirmed that the mass ion values were m/z 208 and m/z 234, and the position of the double bond was the 9th carbon and the 11th carbon, thereby confirming the structure of the conjugated state. Therefore, it was confirmed that the fatty acid obtained by this experiment was c9/t11-conjugated linoleic acid.

Example 4: Optimal CLA Production Using Bifidobacterium breve JKL2022 Cells (Live Cells)

[0080] In this example, Bifidobacterium breve JKL2022 strain (KACC 81214BP) having the highest CLA production activity among various Bifidobacterium strains was used.

[0081] For the production of CLA, the above strain was inoculated into MRS medium (mMRS; Sigma) containing 0.05% L-cysteine HCl and activated through two rounds of subculture at 37 C. for 18 hours under anaerobic conditions where O.sub.2 was replaced with CO.sub.2.

[0082] The activated strain was inoculated into new mMRS medium (200 ml) and cultured at 37 C. for 24 hours under anaerobic conditions to obtain a strain. The culture solution of the strain was centrifuged at 10,000 rpm for 10 minutes at 4 C. The supernatant, which is a medium component, was discarded and recovered the cells collected and washed with PBS (phosphate buffered saline) that was repeated three times. Then, the cells were resuspended again in PBS solution (10 ml), concentrated 20 times, and stored at 4 C. and used as a whole-cell biocatalyst for CLA production. The cells prepared for CLA production using cells were used at the same concentration (1) as when growing in the enrichment medium, and various concentrations of LA were mixed with a reaction buffer to confirm the CLA production efficiency according to the reaction time, reaction temperature, and pH of the reaction solution.

<4-1> CLA Conversion Rate Using Bacteria Whole Cells of the Strain of the Present Invention

[0083] A whole cell pellet was obtained through centrifugation and washing of 1 ml of Bifidobacterium breve JKL2022 culture obtained through enrichment culture in mMRS medium. The microbial whole cell pellet was suspended in a reaction buffer to which LA was added at a concentration of 1.0 mg/ml, and the conversion rate (%) of LA to CLA was confirmed under the conditions of CLA production using cells (pH 7.0, reaction temperature 30 C., reaction time 30 minutes).

[0084] As shown in FIG. 5, CLA production and conversion rate of the strain according to the concentration of LA were investigated while fixing the cell concentration and increasing the amount of LA added. It was confirmed that CLA was produced at a conversion rate of almost 100% within 30 minutes even when the concentration of LA in the reaction solution was increased to 5 mg/ml, and the conversion rate was 70% (7 mg/ml CLA) at a concentration of LA of 10 mg/ml.

[0085] FIG. 6 shows the CLA production characteristics when the concentration of cells was increased by 5 times and the concentration of LA as a substrate was 25 mg/ml. Even under these conditions, it was confirmed that almost all LA could be converted to CLA in one hour of reaction.

[0086] Considering that the upper limit LA concentration of 0.5 mg/ml was due to the antiproliferative effect of LA bacteria in fermentation process, it can be said that the superiority of whole cell biocatalysts is recognized.

[0087] The production of CLA using Bifidobacterium breve JKL2022 cells was about 79 times higher than that obtained through the culture process of Bifidobacterium breve JKL2022 strain. The fact that the reaction using bacterial cells takes only 1 hour, while the production of CLA through culture takes 24 hours, that is a big advantage.

<4-2> Characteristics of Bifidobacterium breve JKL2022 strain

[0088] As shown in FIG. 4, when microbial cells were used as a whole-cell biocatalyst, the production of CLA was confirmed to be a characteristic of only Bifidobacterium breve JKL2022 strain of the present invention. It was found that other strains (FIG. 1) showing the ability to produce CLA by strain culture did not have such characteristics.

<4-3> Confirmation of Optimal Conditions for CLA Production by Bifidobacterium breve JKL2022 Cells

1) Optimal pH Condition

[0089] As shown in FIG. 7, the optimal pH condition for CLA production using the cells of the strain was confirmed to be pH 9.0.

Example 5: Characteristics of CLA Production Using Bifidobacterium breve JKL2022 Cell-Free Extract

<5-1> Preparation of Cell-Free Extract of Disrupted Microbial Strain

[0090] For the production of CLA, Bifidobacterium breve JKL2022 strain (KACC 81214BP) was inoculated into MRS medium (mMRS; Sigma) containing 0.05% L-cysteine HCl and activated through two rounds of subculture at 37 C. for 18 hours under anaerobic conditions where 02 was replaced with CO.sub.2. The activated strain was inoculated into a new mMRS medium (200 ml) and cultured at 37 C. for 24 hours under anaerobic conditions to obtain a strain. The culture solution of the strain was centrifuged at 10,000 rpm for 10 minutes at 4 C. The supernatant, which is a medium component, was recovered to prepare a cell-free extract (CFE) for CLA production and cells collected on the bottom were recovered and washed with PBS (phosphate buffered saline) three times.

[0091] The collected and washed cells were dispersed again in a PBS solution, and the cells were disrupted using an ultrasound sonicator (4s operation, 10s stop pattern, AMP 45% for 10 minutes). All these processes were performed at 4 C. using ice water to prevent enzyme inactivation due to overheating. The disintegrated strain was centrifuged at 12,000 rpm for 15 minutes at 4 C., and the supernatant was recovered to prepare a cell-free extract (CFE), which was used as a crude enzyme solution for CLA production. The production of CLA using CFE was carried out under similar reaction conditions as the production of CLA using the cells in Example 2.

<5-2> Optimal Conditions for CLA Production Using Cell-Free Extract

[0092] To compare the CLA production ability using CFE of Bifidobacterium breve strains prepared by the method of <5-1>, 12.5 l/ml of CFE prepared through strain disruption and 1.0 mg/ml of LA, a substrate, were mixed and the ability of the strains to convert LA to CLA was compared.

[0093] As shown in FIG. 8, the ability to produce CLA using CFE under the condition of pH 6.5 and temperature 35 C. was confirmed to be a characteristic of Bifidobacterium breve JKL2022 strain of the present invention.

1) pH Condition

[0094] The optimal pH and optimal temperature conditions for CLA production using CFE of the strain were confirmed. As shown in FIG. 9, the optimal pH for CLA production using CFE of the strain was 5 to 8, preferably 5.5 to 7, and more preferably 6.5.

2) Temperature Condition

[0095] The optimal pH and optimal temperature conditions for CLA production using CFE of the strain were confirmed. As a result, as shown in FIG. 10, it was confirmed that the optimal temperature for CLA production using CFE of the strain was 20 to 50 C., preferably 30 to 45 C., and more preferably 40 C.

[0096] The production of CLA by CFE of Bifidobacterium breve JKL2022 strain according to the present invention was confirmed with a CLA conversion rate of 46% when LA, a substrate, was used at a concentration of 1.0 mg/ml. Compared to other comparative strains with a CLA conversion rate of less than 3%, the most CLA was produced when CFE of Bifidobacterium breve JKL2022 strain of the present invention was used (FIG. 8).

Accession Number

[0097] Depositary Authority: Korean Agricultural Culture Collection, National Institute of Agricultural Sciences [0098] Deposit Number: Accession Number: KACC 81214BP [0099] Deposit Date: May 11, 2022